JP2012517818A5 - - Google Patents

Download PDF

Info

Publication number
JP2012517818A5
JP2012517818A5 JP2011550552A JP2011550552A JP2012517818A5 JP 2012517818 A5 JP2012517818 A5 JP 2012517818A5 JP 2011550552 A JP2011550552 A JP 2011550552A JP 2011550552 A JP2011550552 A JP 2011550552A JP 2012517818 A5 JP2012517818 A5 JP 2012517818A5
Authority
JP
Japan
Prior art keywords
variable domain
single variable
tnfr1
seq
dom7h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011550552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517818A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/052005 external-priority patent/WO2010094720A2/en
Publication of JP2012517818A publication Critical patent/JP2012517818A/ja
Publication of JP2012517818A5 publication Critical patent/JP2012517818A5/ja
Pending legal-status Critical Current

Links

JP2011550552A 2009-02-19 2010-02-17 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト Pending JP2012517818A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US61/153,746 2009-02-19
US24119809P 2009-09-10 2009-09-10
US61/241,198 2009-09-10
PCT/EP2010/052005 WO2010094720A2 (en) 2009-02-19 2010-02-17 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015151376A Division JP2016007218A (ja) 2009-02-19 2015-07-31 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト

Publications (2)

Publication Number Publication Date
JP2012517818A JP2012517818A (ja) 2012-08-09
JP2012517818A5 true JP2012517818A5 (enExample) 2013-03-07

Family

ID=42136168

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011550552A Pending JP2012517818A (ja) 2009-02-19 2010-02-17 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト
JP2015151376A Pending JP2016007218A (ja) 2009-02-19 2015-07-31 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015151376A Pending JP2016007218A (ja) 2009-02-19 2015-07-31 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト

Country Status (14)

Country Link
US (1) US20110301335A1 (enExample)
EP (1) EP2398827A2 (enExample)
JP (2) JP2012517818A (enExample)
KR (1) KR20110119806A (enExample)
CN (1) CN102405236A (enExample)
AU (1) AU2010215479B2 (enExample)
BR (1) BRPI1008014A2 (enExample)
CA (1) CA2750477A1 (enExample)
EA (1) EA022925B1 (enExample)
IL (1) IL214648A0 (enExample)
MX (1) MX2011008799A (enExample)
SG (1) SG173173A1 (enExample)
WO (1) WO2010094720A2 (enExample)
ZA (1) ZA201105627B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) * 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
KR101819754B1 (ko) 2009-02-19 2018-01-18 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
US20120107330A1 (en) * 2009-07-16 2012-05-03 Adriaan Allart Stoop Antagonists, uses & methods for partially inhibiting tnfr1
PH12012500826A1 (en) * 2009-10-27 2013-01-07 Glaxo Group Ltd Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
KR101871008B1 (ko) * 2010-09-16 2018-06-25 발리오팜 아게 항-huTNFR1 항체
WO2012172070A1 (en) * 2011-06-17 2012-12-20 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
CN107043413A (zh) * 2016-02-05 2017-08-15 华中农业大学 一种肺结核相关的尿液生物标志蛋白及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US12352766B2 (en) * 2019-01-31 2025-07-08 Sekisui Medical Co., Ltd. Immunoassay method for free aim in biological sample, and method for detecting NASH in subject
US12472266B2 (en) 2019-02-21 2025-11-18 Enosi Therapeutics Corporation Antibodies and enonomers
IL300930A (en) * 2020-08-27 2023-04-01 Enosi Therapeutics Corp Methods and compositions for the treatment of autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2025021184A1 (zh) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 编码尿酸氧化酶的多核苷酸及其相关组合物和方法
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
WO1999002671A1 (en) 1997-07-07 1999-01-21 Medical Research Council In vitro sorting method
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
AU2001238076A1 (en) 2000-02-11 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
ES2315664T3 (es) 2003-06-30 2009-04-01 Domantis Limited Anticuerpos de dominio unico (dab) pegilados.
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
EP2172553A1 (en) 2004-03-24 2010-04-07 Domantis Limited Gas1 universal leader
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
JP2009519011A (ja) * 2005-12-01 2009-05-14 ドマンティス リミテッド インターロイキン1受容体1型に結合する非競合ドメイン抗体フォーマット
US20100056439A1 (en) * 2005-12-06 2010-03-04 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
US7868885B2 (en) 2007-06-22 2011-01-11 Microsoft Corporation Direct manipulation of subdivision surfaces using a graphics processing unit
US20120107330A1 (en) * 2009-07-16 2012-05-03 Adriaan Allart Stoop Antagonists, uses & methods for partially inhibiting tnfr1
CN102574914A (zh) * 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
PH12012500826A1 (en) * 2009-10-27 2013-01-07 Glaxo Group Ltd Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists

Similar Documents

Publication Publication Date Title
JP2012517818A5 (enExample)
JP2010530220A5 (enExample)
US9708402B2 (en) Anti-BAFF-anti-IL-17 bispecific antibodies
JP2018108081A5 (enExample)
JP2009539349A5 (enExample)
JP2017500018A5 (enExample)
CN109311974A (zh) 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
JP2012532619A5 (enExample)
JP2012021001A5 (enExample)
JP2019521647A5 (enExample)
JP2017523786A5 (enExample)
CN114980974A (zh) 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽
JP2019522961A5 (enExample)
JP2011526792A5 (enExample)
JP2018521691A5 (enExample)
JP2016529232A (ja) サイトカインアンタゴニストの標的化
JP2008525033A5 (enExample)
JP2014500009A5 (enExample)
JP2009518005A5 (enExample)
HRP20150799T1 (hr) Sastavi i postupci za protutijela protiv komplementnog proteina c5
JP2012528110A5 (enExample)
JP2008501716A5 (enExample)
JP2014503209A5 (enExample)
ES2822431T3 (es) Polipéptidos de unión a IL-17A
JP2014516945A5 (enExample)